Insulet Co. (NASDAQ:PODD) Shares Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its stake in Insulet Co. (NASDAQ:PODD) by 9.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 18,916 shares of the medical instruments supplier’s stock after purchasing an additional 1,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in Insulet were worth $4,938,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Private Advisor Group LLC lifted its holdings in Insulet by 30.5% in the 4th quarter. Private Advisor Group LLC now owns 9,642 shares of the medical instruments supplier’s stock valued at $2,517,000 after purchasing an additional 2,255 shares in the last quarter. Alberta Investment Management Corp lifted its holdings in Insulet by 57.6% in the 4th quarter. Alberta Investment Management Corp now owns 3,400 shares of the medical instruments supplier’s stock valued at $888,000 after purchasing an additional 1,242 shares in the last quarter. Global Retirement Partners LLC lifted its holdings in Insulet by 560.2% in the 4th quarter. Global Retirement Partners LLC now owns 647 shares of the medical instruments supplier’s stock valued at $169,000 after purchasing an additional 549 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in Insulet by 1,047.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,767 shares of the medical instruments supplier’s stock valued at $461,000 after purchasing an additional 1,613 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its holdings in Insulet by 4.7% in the 4th quarter. CIBC Asset Management Inc now owns 10,679 shares of the medical instruments supplier’s stock valued at $2,788,000 after purchasing an additional 476 shares in the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research reports. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Stifel Nicolaus raised their price objective on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a report on Friday. Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Morgan Stanley lifted their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, Wells Fargo & Company raised their price objective on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $289.06.

Insider Buying and Selling at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of Insulet stock opened at $282.80 on Monday. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The company has a market cap of $19.84 billion, a PE ratio of 48.84, a P/E/G ratio of 3.62 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The business has a 50-day simple moving average of $272.98 and a 200-day simple moving average of $247.87.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, equities research analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.